Advertisement

The Changing Face of cN0M0 Prostate Cancer Being Found With pN+ After Surgery in the Contemporary Era: Results of an International European Survey on Disease Management

Published:December 05, 2022DOI:https://doi.org/10.1016/j.clgc.2022.11.012

      Abstract

      Introduction

      The urological community's opinion over the management of men being found with pathologically positive nodes (pN+) following radical prostatectomy (RP) performed with curative intent after preoperative negative conventional staging (cN0M0) has never been assessed. This remains crucial, especially considering the advent of novel imaging modalities. Our aim was to investigate the current opinion on management of pN+ cN0M0 prostate cancer (PCa) in the European urological community.

      Methods

      Following validation, a 31-item survey, complying with the Cherries checklist, was distributed using a web link from December 2021 to April 2022 to 10 urological societies mailing list. Social media (Twitter, Facebook) were also used.

      Results

      We received 253 replies. The majority were Urologists (96.8%), younger than 60 (90.5%); 5.2% did not have access to PET-scans; 78.9% believed pN+ is a multifaceted category; 10-years CSS was marked as 71 to 95% by 17.5%. Gold standard management was stated not being ADT by 80.8% and being RT±ADT by 52.3%. Early sRT±ADT was considered an option vs. aRT±ADT by 72.4%. In case of BCR 71% would perform and decide management based on PSMA-PET whilst 3.7% would not perform PSMA-PET. pN+ management is still unclear for 77.1%. On multivariate analysis PSMA-PET availability related to a lower and higher likelihood of considering aRT±ADT as standard and of considering early salvage versus aRT respectively (P < .05).

      Conclusions

      The Urological community has an acceptable awareness of pN+ disease and management, although it may overestimate disease aggressiveness. The majority consider pN+ PCa as a multifaceted category and rely on a risk-adapted approach. Expectant compared to immediate upfront management and new imaging modalities are increasingly considered.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Genitourinary Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Tyson M.D.
        • et al.
        Radical Prostatectomy Trends in the United States: 1998 to 2011.
        Mayo Clin Proc. 2016; 91: 10-16
      1. EAU Guidelines. Edn. Presented at the EAU Annual Congress Amsterdam 2022. Available at: https://uroweb.org/guidelines/prostate-cancer/chapter/citation-information.6.1.2.3.7. Accessed date 1st August 2022.

        • Laine C.
        • et al.
        Features and management of men with pN1 cM0 prostate cancer after radical prostatectomy and lymphadenectomy: a systematic review of population-based evidence.
        Curr Opin Urol. 2022; 32: 69-84
        • Moschini M.
        • et al.
        Risk Stratification of pN+ Prostate Cancer after Radical Prostatectomy from a Large Single Institutional Series with Long-Term Followup.
        J Urol. 2016; 195: 1773-1778
        • Abdollah F.
        • et al.
        Extended pelvic lymph node dissection in prostate cancer: a 20-year audit in a single center.
        Ann Oncol. 2013; 24: 1459-1466
        • Mandel P.
        • et al.
        Association between lymph node counts and oncological outcomes in lymph node positive prostate cancer.
        Eur Urol Focus. 2017; 3: 248-255
        • Touijer K.A.
        • Mazzola C.R.
        • Sjoberg D.D.
        • Scardino P.T.
        • Eastham J.A.
        Long-term outcomes of patients with lymph node metastasis treated with radical prostatectomy without adjuvant androgen-deprivation therapy.
        Eur Urol. 2014; 65: 20-25
        • Messing E.M.
        • et al.
        Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy.
        Lancet Oncol. 2006; 7: 472-479
        • Messing E.M.
        • et al.
        Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer.
        N Engl J Med. 1999; 341: 1781-1788
        • Marra G.
        • et al.
        Management of Patients with Node-positive Prostate Cancer at Radical Prostatectomy and Pelvic Lymph Node Dissection: A Systematic Review.
        Eur Urol Oncol. 2020; 3: 565-581
        • Eysenbach G.
        Improving the quality of web surveys: the Checklist for Reporting Results of Internet E-Surveys (CHERRIES).
        J Med Inter Res. 2004; 6: e34
        • Bianchi L.
        • et al.
        Evaluating the predictive accuracy and the clinical benefit of a nomogram aimed to predict survival in node-positive prostate cancer patients: External validation on a multi-institutional database.
        Int J Urol. 2018; 25: 574-581
        • Abdollah F.
        • et al.
        Impact of adjuvant radiotherapy on survival of patients with node-positive prostate cancer.
        J Clin Oncol. 2014; 32: 3939-3947
        • Vale C.L.
        • et al.
        Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data.
        Lancet North Am Ed. 2020; 396: 1422-1431
        • Tilki D.
        • et al.
        Adjuvant versus early salvage radiation therapy for men at high risk for recurrence following radical prostatectomy for prostate cancer and the risk of death.
        J Clin Oncol. 2021; 39: 2284-2293
        • Pozdnyakov A.
        • et al.
        The impact of PSMA PET on the treatment and outcomes of men with biochemical recurrence of prostate cancer: a systematic review and meta-analysis.
        Prostate Cancer Prostatic Dis. 2022; https://doi.org/10.1038/s41391-022-00544-3
        • Hofman M.S.
        • et al.
        Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study.
        Lancet North Am Ed. 2020; 395: 1208-1216
        • Emmett L.
        • et al.
        The additive diagnostic value of prostate-specific membrane antigen positron emission tomography computed tomography to multiparametric magnetic resonance imaging triage in the diagnosis of prostate cancer (PRIMARY): a prospective multicentre study.
        Eur Urol. 2021; 80: 682-689
        • Murphy D.G.
        • Padhani A.R.
        • Ost P.
        Adding colour to the grey zone of advanced prostate cancer.
        Eur Urol Focus. 2019; 5: 123-124
        • Marra G.
        • et al.
        Focal therapy in localised prostate cancer: real-world urological perspective explored in a cross-sectional European survey.
        Urol Oncol. 2018; 36: 529.e11-529.e22
        • Surcel C.I.
        • et al.
        Preferences in the management of high-risk prostate cancer among urologists in Europe: results of a web-based survey.
        BJU Int. 2015; 115: 571-579